|
US8586781B2
(en)
|
1998-04-02 |
2013-11-19 |
Mbc Pharma, Inc. |
Bone targeted therapeutics and methods of making and using the same
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
DK1620544T3
(en)
*
|
2003-04-17 |
2019-01-14 |
Alnylam Pharmaceuticals Inc |
MODIFIED iRNA AGENTS
|
|
US8575327B2
(en)
|
2003-06-12 |
2013-11-05 |
Alnylam Pharmaceuticals, Inc. |
Conserved HBV and HCV sequences useful for gene silencing
|
|
US9393315B2
(en)
|
2011-06-08 |
2016-07-19 |
Nitto Denko Corporation |
Compounds for targeting drug delivery and enhancing siRNA activity
|
|
AU2007299629C1
(en)
|
2006-09-21 |
2012-05-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the HAMP gene
|
|
WO2009082607A2
(en)
*
|
2007-12-04 |
2009-07-02 |
Alnylam Pharmaceuticals, Inc. |
Targeting lipids
|
|
EP2231194B1
(en)
*
|
2007-12-04 |
2017-02-22 |
Alnylam Pharmaceuticals Inc. |
Folate-irna conjugates
|
|
WO2009126933A2
(en)
|
2008-04-11 |
2009-10-15 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
|
CA2746527A1
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
|
MX2011004097A
(es)
|
2008-10-15 |
2011-07-28 |
Isis Pharmaceuticals Inc |
Modulacion de la expresion del factor 11.
|
|
EA036772B1
(ru)
|
2008-10-20 |
2020-12-18 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы для ингибирования экспрессии транстиретина
|
|
HUE037082T2
(hu)
|
2008-11-10 |
2018-08-28 |
Arbutus Biopharma Corp |
Új lipidek és készítmények terápiás hatóanyagok szállítására
|
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
|
EP3243504A1
(en)
*
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
EP2669290A1
(en)
|
2009-03-02 |
2013-12-04 |
Alnylam Pharmaceuticals Inc. |
Nucleic Acid Chemical Modifications
|
|
ES2804764T3
(es)
|
2009-06-01 |
2021-02-09 |
Halo Bio Rnai Therapeutics Inc |
Polinucleótidos para la interferencia de ARN multivalente, composiciones y métodos de uso de los mismos
|
|
NZ597504A
(en)
*
|
2009-06-15 |
2013-10-25 |
Alnylam Pharmaceuticals Inc |
Lipid formulated dsrna targeting the pcsk9 gene
|
|
US9101643B2
(en)
|
2009-11-03 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
|
|
HUE042177T2
(hu)
|
2009-12-01 |
2019-06-28 |
Translate Bio Inc |
Szteroidszármazék mRNS szállítására humán genetikai betegségekben
|
|
WO2011102905A1
(en)
*
|
2010-02-19 |
2011-08-25 |
Robert Shorr |
Imageable lipid-oil-water nanoemulsion diagnostic delivery system
|
|
WO2011102904A1
(en)
*
|
2010-02-19 |
2011-08-25 |
Robert Shorr |
Imageable lipid-oil-water nanoemulsion therapeutic delivery system
|
|
WO2011102906A1
(en)
*
|
2010-02-19 |
2011-08-25 |
Robert Shorr |
Imageable lipid-oil-water nanoemulsion delivery system
|
|
US9080171B2
(en)
*
|
2010-03-24 |
2015-07-14 |
RXi Parmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
|
BR112012024049A2
(pt)
|
2010-03-24 |
2017-03-01 |
Rxi Pharmaceuticals Corp |
interferência de rna em indicações dérmicas e fibróticas
|
|
CA2792561C
(en)
|
2010-04-06 |
2021-10-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of cd274/pd-l1 gene
|
|
DK2558578T3
(en)
|
2010-04-13 |
2016-01-25 |
Life Technologies Corp |
CONFIGURATIONS AND METHODS FOR INHIBITION OF nucleic acid function
|
|
WO2011133871A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
5'-end derivatives
|
|
CA2800693A1
(en)
|
2010-05-28 |
2011-12-01 |
Purdue Research Foundation |
Delivery of therapeutic agents to inflamed tissues using folate-targeted agents
|
|
US8785121B2
(en)
|
2010-07-08 |
2014-07-22 |
Bonac Corporation |
Single-stranded nucleic acid molecule for controlling gene expression
|
|
AU2011282977A1
(en)
*
|
2010-07-28 |
2013-02-21 |
Smartcells, Inc. |
Drug-ligand conjugates, synthesis thereof, and intermediates thereto
|
|
US8691782B2
(en)
|
2010-08-03 |
2014-04-08 |
Bonac Corporation |
Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
|
|
ES2527660T3
(es)
*
|
2010-08-03 |
2015-01-28 |
Bonac Corporation |
Molécula de ARN monocatenario que tiene esqueleto alicíclico que contiene nitrógeno
|
|
WO2012027206A1
(en)
|
2010-08-24 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
|
|
CA2812046A1
(en)
|
2010-09-15 |
2012-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified irna agents
|
|
CN101974152B
(zh)
*
|
2010-09-28 |
2012-07-11 |
山东大学 |
一种类脂-阳离子聚合物及其制备方法
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
CA3077910A1
(en)
|
2010-11-17 |
2012-05-24 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
|
EP2652134B1
(en)
|
2010-12-17 |
2017-03-01 |
Arrowhead Pharmaceuticals, Inc. |
Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
|
|
ES2605990T3
(es)
|
2010-12-29 |
2017-03-17 |
F. Hoffmann-La Roche Ag |
Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos
|
|
CA2824526C
(en)
|
2011-01-11 |
2020-07-07 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
|
KR102365961B1
(ko)
|
2011-03-29 |
2022-02-23 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
|
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
|
PL3586861T3
(pl)
|
2011-06-08 |
2022-05-23 |
Translate Bio, Inc. |
Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
|
|
EP2723861A4
(en)
*
|
2011-06-21 |
2014-12-10 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
|
|
ES2923573T3
(es)
|
2011-06-21 |
2022-09-28 |
Alnylam Pharmaceuticals Inc |
Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas
|
|
CN103649103A
(zh)
|
2011-06-21 |
2014-03-19 |
阿尔尼拉姆医药品有限公司 |
用于抑制载脂蛋白c-iii(apoc3)基因表达的组合物与方法
|
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
|
EP3366312A1
(en)
*
|
2011-06-23 |
2018-08-29 |
Alnylam Pharmaceuticals, Inc. |
Serpina 1 sirnas: compositions of matter and methods of treatment
|
|
HRP20181564T1
(hr)
|
2011-06-30 |
2018-11-30 |
Arrowhead Pharmaceuticals, Inc. |
Pripravci i postupci za inhibiciju ekspresije gena virusa hepatitisa b
|
|
CA2843885C
(en)
|
2011-08-01 |
2020-03-10 |
Mbc Pharma, Inc. |
Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
|
|
EP3453761A1
(en)
|
2011-08-29 |
2019-03-13 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
EP2760477B1
(en)
|
2011-09-27 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
|
EP2594575A1
(en)
*
|
2011-11-15 |
2013-05-22 |
Université de Strasbourg |
Mannosylated compounds useful for the prevention and the treatment of infectious diseases
|
|
EP2780454A2
(en)
|
2011-11-18 |
2014-09-24 |
Alnylam Pharmaceuticals, Inc. |
Modified rnai agents
|
|
HUE048622T2
(hu)
*
|
2011-11-18 |
2020-08-28 |
Alnylam Pharmaceuticals Inc |
RNSi szerek, készítmények és alkalmazási eljárások transztiretin (TTR) asszociált betegségek kezelésére
|
|
EP2788006B1
(en)
|
2011-12-07 |
2026-01-07 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
MX375673B
(es)
|
2012-04-02 |
2025-03-06 |
Berg Llc |
Ensayos basados en interrogatorios celulares y usos de los mismos.
|
|
US9133461B2
(en)
*
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
US9127274B2
(en)
*
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
AR090906A1
(es)
*
|
2012-05-02 |
2014-12-17 |
Merck Sharp & Dohme |
Conjugados que contienen tetragalnac y procedimientos para la administracion de oligonucleotidos
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
US20160002624A1
(en)
|
2012-05-17 |
2016-01-07 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
|
CN109810977A
(zh)
|
2012-05-26 |
2019-05-28 |
株式会社博纳克 |
具有递送功能的基因表达调控用单链核酸分子
|
|
MX369768B
(es)
|
2012-06-01 |
2019-11-21 |
Berg Llc |
Composición farmacéutica de coenzima q10 para usarse en un método para tratar cáncer.
|
|
WO2013183656A1
(ja)
*
|
2012-06-04 |
2013-12-12 |
大日本住友製薬株式会社 |
Ｇタンパク質共役受容体結合リガンドと核酸分子とのコンジュゲート
|
|
EP3536787A1
(en)
|
2012-06-08 |
2019-09-11 |
Translate Bio, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
US10245229B2
(en)
|
2012-06-08 |
2019-04-02 |
Translate Bio, Inc. |
Pulmonary delivery of mRNA to non-lung target cells
|
|
JP6427097B2
(ja)
|
2012-06-15 |
2018-11-21 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． |
癌を処置するための組成物および該組成物を製造するための方法
|
|
AU2013299717B2
(en)
*
|
2012-08-06 |
2018-06-28 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugated RNA agents and process for their preparation
|
|
CN102824515B
(zh)
*
|
2012-09-18 |
2015-05-20 |
淄博齐鼎立专利信息咨询有限公司 |
热毒清片在制备抑制a-204细胞增殖药物中的应用
|
|
MX2015005328A
(es)
|
2012-10-26 |
2015-09-25 |
Nlife Therapeutics S L |
Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas.
|
|
US10077443B2
(en)
|
2012-11-15 |
2018-09-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
|
US9506897B2
(en)
|
2012-11-16 |
2016-11-29 |
Agilent Technologies, Inc. |
Methods and compositions for improved ion-exchange chromatography
|
|
US10125369B2
(en)
*
|
2012-12-05 |
2018-11-13 |
Alnylam Pharmaceuticals, Inc. |
PCSK9 iRNA compositions and methods of use thereof
|
|
US20150337318A1
(en)
*
|
2013-01-11 |
2015-11-26 |
Phaserx Inc. |
Rna targeted to c-met
|
|
CN104955952A
(zh)
*
|
2013-01-30 |
2015-09-30 |
弗·哈夫曼-拉罗切有限公司 |
Lna寡核苷酸碳水化合物缀合物
|
|
KR20210122917A
(ko)
|
2013-03-14 |
2021-10-12 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Cftr mrna 조성물 및 관련 방법 및 사용
|
|
CA3216595A1
(en)
|
2013-03-14 |
2014-10-02 |
Kevin Fitzgerald |
Complement component c5 irna compositions and methods of use thereof
|
|
DK2970456T3
(da)
|
2013-03-14 |
2021-07-05 |
Translate Bio Inc |
Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer
|
|
PL3467108T3
(pl)
|
2013-03-14 |
2024-09-30 |
Translate Bio, Inc. |
Sposoby oczyszczania informacyjnego rna
|
|
CA2902571A1
(en)
|
2013-03-15 |
2014-09-18 |
MiRagen Therapeutics, Inc. |
Bridged bicyclic nucleosides
|
|
US10130649B2
(en)
|
2013-03-15 |
2018-11-20 |
Translate Bio, Inc. |
Synergistic enhancement of the delivery of nucleic acids via blended formulations
|
|
SG10201903112WA
(en)
|
2013-04-08 |
2019-05-30 |
Berg Llc |
Treatment of cancer using coenzyme q10 combination therapies
|
|
CN105164261B
(zh)
*
|
2013-05-01 |
2022-03-18 |
莱古路斯治疗法股份有限公司 |
用于增强的细胞摄取的化合物和方法
|
|
SG11201508925WA
(en)
|
2013-05-01 |
2015-11-27 |
Regulus Therapeutics Inc |
Microrna compounds and methods for modulating mir-122
|
|
DK2991656T3
(da)
|
2013-05-01 |
2020-03-23 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
|
|
WO2014182661A2
(en)
|
2013-05-06 |
2014-11-13 |
Alnylam Pharmaceuticals, Inc |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
|
RU2535052C1
(ru)
*
|
2013-05-21 |
2014-12-10 |
Владимир Николаевич Иванов |
Фармацевтическая композиция, содержащая производные лизина, пролина и тритерпеновой кислоты для лечения и профилактики вирусных инфекций, вызываемых рнк и днк-содержащими вирусами, такими как: грипп, герпес, опоясывающий лишай, папиллома человека, аденоновирусы, а также бактериальных инфекций, вызываемых грам-положительными и грам-отрицательными микроорганизмами
|
|
KR102486617B1
(ko)
*
|
2013-05-22 |
2023-01-12 |
알닐람 파마슈티칼스 인코포레이티드 |
Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법
|
|
TW201936624A
(zh)
*
|
2013-05-22 |
2019-09-16 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
|
|
EP3564374A1
(en)
|
2013-06-21 |
2019-11-06 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
|
ES2770667T3
(es)
|
2013-06-27 |
2020-07-02 |
Roche Innovation Ct Copenhagen As |
Oligómeros antisentido y conjugados que se dirigen a PCSK9
|
|
CN105705638B
(zh)
*
|
2013-07-05 |
2019-11-26 |
柏业公司 |
改善的具有高效能的纳米颗粒型寡核苷酸结构及其制备方法
|
|
JP6702862B2
(ja)
|
2013-07-11 |
2020-06-03 |
アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
オリゴヌクレオチド−リガンドコンジュゲートおよびそれらの調製方法
|
|
KR102370843B1
(ko)
|
2013-09-04 |
2022-03-04 |
버그 엘엘씨 |
코엔자임 q10의 연속주입에 의한 암치료 방법
|
|
EP3046585B1
(en)
|
2013-09-17 |
2021-08-25 |
Bolt Threads, Inc. |
Methods and compositions for synthesizing improved silk fibers
|
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
TW201610151A
(zh)
|
2013-09-23 |
2016-03-16 |
阿尼拉製藥公司 |
治療或預防與甲狀腺素運載蛋白相關疾病之方法
|
|
US10077444B2
(en)
*
|
2013-10-02 |
2018-09-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
|
TWI768330B
(zh)
|
2013-10-04 |
2022-06-21 |
美國西奈山伊坎醫學院 |
抑制alas1基因表現的組合物及方法
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
AU2014340149B2
(en)
|
2013-10-22 |
2020-12-24 |
Shire Human Genetic Therapies, Inc. |
CNS delivery of mRNA and uses thereof
|
|
ES2707966T3
(es)
|
2013-10-22 |
2019-04-08 |
Translate Bio Inc |
Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
|
|
EA034103B1
(ru)
|
2013-10-22 |
2019-12-27 |
Транслейт Био, Инк. |
СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
|
|
MX2016005238A
(es)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
|
|
US9994846B2
(en)
|
2013-10-25 |
2018-06-12 |
Regulus Therapeutics Inc. |
MicroRNA compounds and methods for modulating miR-21 activity
|
|
KR20160083876A
(ko)
*
|
2013-11-14 |
2016-07-12 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
ApoB 안티센스 접합체 화합물
|
|
WO2015084897A2
(en)
|
2013-12-02 |
2015-06-11 |
Mirimmune, Llc |
Immunotherapy of cancer
|
|
SG10201804960RA
(en)
|
2013-12-12 |
2018-07-30 |
Alnylam Pharmaceuticals Inc |
Complement component irna compositions and methods of use thereof
|
|
CN105899663B
(zh)
|
2013-12-26 |
2019-07-26 |
学校法人东京医科大学 |
用于基因表达控制的人工模拟miRNA及其用途
|
|
SG10201913570XA
(en)
|
2013-12-27 |
2020-03-30 |
Bonac Corp |
Artificial match-type mirna for controlling gene expression and use therefor
|
|
WO2015106128A2
(en)
*
|
2014-01-09 |
2015-07-16 |
Alnylam Pharmaceuticals, Inc. |
MODIFIED RNAi AGENTS
|
|
JP6584412B2
(ja)
*
|
2014-01-15 |
2019-10-02 |
ベースクリック ゲーエムベーハー |
糖修飾核酸分子
|
|
WO2015113922A1
(en)
*
|
2014-01-30 |
2015-08-06 |
Roche Innovation Center Copenhagen A/S |
Poly oligomer compound with biocleavable conjugates
|
|
AU2015217301A1
(en)
|
2014-02-11 |
2016-08-25 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
|
|
CN106103717A
(zh)
|
2014-03-19 |
2016-11-09 |
Ionis制药公司 |
用于调节共济失调蛋白2表达的组合物
|
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
|
RS60707B1
(sr)
|
2014-04-01 |
2020-09-30 |
Biogen Ma Inc |
Kompozicije za modulaciju ekspresije sod-1
|
|
KR20160132496A
(ko)
|
2014-04-03 |
2016-11-18 |
인빅터스 온콜로지 피비티. 엘티디. |
초분자 조합 치료제
|
|
PT3134506T
(pt)
|
2014-04-25 |
2019-10-31 |
Translate Bio Inc |
Métodos de purificação de rna mensageiro
|
|
DK3137476T3
(da)
|
2014-04-28 |
2019-11-18 |
Ionis Pharmaceuticals Inc |
Linker-modificerede oligomerforbindelser
|
|
US11279934B2
(en)
|
2014-04-28 |
2022-03-22 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
|
|
SG11201608502TA
(en)
|
2014-05-01 |
2016-11-29 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating complement factor b expression
|
|
EP3862362A3
(en)
|
2014-05-01 |
2021-10-27 |
Ionis Pharmaceuticals, Inc. |
Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
|
|
PT3137605T
(pt)
|
2014-05-01 |
2020-12-18 |
Ionis Pharmaceuticals Inc |
Composições e métodos para modulação da expressão de angiopoietina de tipo 3
|
|
CN110903337A
(zh)
*
|
2014-05-01 |
2020-03-24 |
Ionis制药公司 |
用于调节生长激素受体表达的组合物和方法
|
|
US10098959B2
(en)
|
2014-05-01 |
2018-10-16 |
Ionis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
|
|
CA3215908A1
(en)
|
2014-05-22 |
2015-11-26 |
Alnylam Pharmaceuticals, Inc. |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
JP6557722B2
(ja)
|
2014-05-30 |
2019-08-07 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
核酸の送達のための生分解性脂質
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
EP3160959B1
(en)
|
2014-06-24 |
2023-08-30 |
Translate Bio, Inc. |
Stereochemically enriched compositions for delivery of nucleic acids
|
|
SMT202200502T1
(it)
|
2014-06-25 |
2023-01-13 |
Acuitas Therapeutics Inc |
Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
|
|
BR112016030852A2
(pt)
|
2014-07-02 |
2018-01-16 |
Shire Human Genetic Therapies |
encapsulação de rna mensageiro
|
|
TW201613949A
(en)
|
2014-08-07 |
2016-04-16 |
Regulus Therapeutics Inc |
Targeting microRNAs for metabolic disorders
|
|
WO2016030863A1
(en)
|
2014-08-29 |
2016-03-03 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds and methods for treating viral infections
|
|
DK3185957T3
(da)
|
2014-08-29 |
2022-08-29 |
Alnylam Pharmaceuticals Inc |
Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
|
|
KR102506169B1
(ko)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
|
BR112017004056A2
(pt)
|
2014-09-12 |
2017-12-05 |
Biogen Ma Inc |
composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
|
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
|
CN107109411B
(zh)
|
2014-10-03 |
2022-07-01 |
冷泉港实验室 |
核基因输出的定向增加
|
|
TWI864340B
(zh)
|
2014-10-10 |
2024-12-01 |
美商艾爾妮蘭製藥公司 |
用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
|
|
WO2016055601A1
(en)
|
2014-10-10 |
2016-04-14 |
F. Hoffmann-La Roche Ag |
Galnac phosphoramidites, nucleic acid conjugates thereof and their use
|
|
US20170304459A1
(en)
*
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
EP3212794B1
(en)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
|
TWI710633B
(zh)
|
2014-11-10 |
2020-11-21 |
美商阿尼拉製藥公司 |
Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法
|
|
EP3240411A4
(en)
|
2014-11-12 |
2019-02-20 |
Tumorend LLC |
COMPOSITIONS, METHODS AND TREATMENTS FOR INHIBITING CELL ADHESION AND VIRUS BINDING AND PENETRATION
|
|
JP2017533721A
(ja)
|
2014-11-14 |
2017-11-16 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
タンパク質の調節のための化合物及び方法
|
|
HK1244843A1
(zh)
|
2014-11-17 |
2018-08-17 |
Alnylam Pharmaceuticals, Inc. |
载脂蛋白c3(apoc3)irna组合物及其使用方法
|
|
WO2016085852A1
(en)
|
2014-11-24 |
2016-06-02 |
Alnylam Pharmaceuticals, Inc. |
Tmprss6 irna compositions and methods of use thereof
|
|
WO2016090262A1
(en)
|
2014-12-05 |
2016-06-09 |
Shire Human Genetic Therapies, Inc. |
Messenger rna therapy for treatment of articular disease
|
|
SG10202012249YA
(en)
|
2014-12-08 |
2021-01-28 |
Berg Llc |
Use of markers including filamin a in the diagnosis and treatment of prostate cancer
|
|
EP4372091A3
(en)
|
2014-12-12 |
2024-07-31 |
Tod M. Woolf |
Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
|
|
JP7105065B2
(ja)
*
|
2014-12-15 |
2022-07-22 |
ダイセルナ ファーマシューティカルズ， インコーポレイテッド |
リガンド修飾二本鎖核酸
|
|
CA2970795A1
(en)
|
2014-12-18 |
2016-06-23 |
Alnylam Pharmaceuticals, Inc. |
Reversir compounds
|
|
EP4349414B1
(en)
*
|
2014-12-23 |
2025-10-15 |
Dyve Biosciences, Inc. |
Formulations for transdermal administration
|
|
SG11201705223XA
(en)
|
2014-12-27 |
2017-07-28 |
Bonac Corp |
NATURALLY OCCURING miRNA FOR CONTROLLING GENE EXPRESSION, AND USE OF SAME
|
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
|
WO2016123628A1
(en)
*
|
2015-01-30 |
2016-08-04 |
The Regents Of The University Of Colorado, A Body Corporate |
Sequence specific and organism specific antimicrobials and related materials and methods
|
|
WO2016130806A2
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
CN104804463B
(zh)
*
|
2015-03-10 |
2016-08-24 |
西安交通大学第一附属医院 |
用于靶向肿瘤组织的近红外荧光染色剂及制备方法和应用
|
|
US10172924B2
(en)
|
2015-03-19 |
2019-01-08 |
Translate Bio, Inc. |
MRNA therapy for pompe disease
|
|
JP6602847B2
(ja)
|
2015-03-27 |
2019-11-06 |
株式会社ボナック |
デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
|
|
MX2017012426A
(es)
|
2015-04-03 |
2018-01-26 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de tmprss6.
|
|
EP3277811B1
(en)
|
2015-04-03 |
2020-12-23 |
University of Massachusetts |
Fully stabilized asymmetric sirna
|
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
EA201792263A1
(ru)
|
2015-04-13 |
2018-08-31 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
US10709728B2
(en)
|
2015-06-01 |
2020-07-14 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereof
|
|
CN104987360A
(zh)
|
2015-06-04 |
2015-10-21 |
大连民族学院 |
一类双烷氧酰胺烷基阳离子肽脂质及其合成方法和应用
|
|
EP4365291A3
(en)
|
2015-06-12 |
2024-08-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
CA3012607A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzymes and systems
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
LT3313829T
(lt)
|
2015-06-29 |
2024-08-12 |
Acuitas Therapeutics Inc. |
Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui
|
|
GB201511459D0
(en)
*
|
2015-06-30 |
2015-08-12 |
Cell Therapy Ltd |
Sirna microbubble
|
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
|
CN108135923B
(zh)
|
2015-07-06 |
2021-03-02 |
菲奥医药公司 |
靶向超氧化物歧化酶1（sod1）的核酸分子
|
|
CA2991894A1
(en)
|
2015-07-10 |
2017-01-19 |
Ionis Pharmaceuticals, Inc. |
Modulators of diacyglycerol acyltransferase 2 (dgat2)
|
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
|
EP3919619A1
(en)
|
2015-07-17 |
2021-12-08 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
|
TW201718620A
(zh)
|
2015-07-27 |
2017-06-01 |
阿尼拉製藥公司 |
黃嘌呤脫氫酶（ＸＤＨ）ｉＲＮＡ組成物及其使用方法
|
|
CN108138182B
(zh)
|
2015-07-31 |
2022-08-19 |
阿尔尼拉姆医药品有限公司 |
甲状腺素运载蛋白(TTR)iRNA组合物及其治疗或预防TTR相关疾病的使用方法
|
|
EP3328439B1
(en)
|
2015-07-31 |
2020-04-08 |
Arcturus Therapeutics, Inc. |
Multiligand agent for drug delivery
|
|
KR20180038465A
(ko)
|
2015-08-07 |
2018-04-16 |
애로우헤드 파마슈티컬스 인코포레이티드 |
Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
|
|
US10633653B2
(en)
|
2015-08-14 |
2020-04-28 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
|
JP2018525037A
(ja)
|
2015-08-24 |
2018-09-06 |
ハロー−バイオ・アールエヌエーアイ・セラピューティックス、インコーポレイテッド |
遺伝子発現の調節のためのポリヌクレオチドナノ粒子及びその使用
|
|
CN118697894A
(zh)
|
2015-08-25 |
2024-09-27 |
阿尔尼拉姆医药品有限公司 |
用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
|
|
KR20250145703A
(ko)
|
2015-09-02 |
2025-10-13 |
알닐람 파마슈티칼스 인코포레이티드 |
프로그램된 세포사 1 리간드 1 (PD-L1) iRNA 조성물 및 그의 사용 방법
|
|
JP6877414B2
(ja)
|
2015-09-24 |
2021-05-26 |
アイオニス・ファーマシューティカルズ・インコーポレイテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
Ｋｒａｓ発現のモジュレーター
|
|
US10533175B2
(en)
|
2015-09-25 |
2020-01-14 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating Ataxin 3 expression
|
|
CN113817735A
(zh)
|
2015-10-08 |
2021-12-21 |
Ionis制药公司 |
用于调节血管紧张素原表达的化合物和方法
|
|
EP3359640A4
(en)
*
|
2015-10-09 |
2019-03-20 |
Dice Molecules SV, LLC |
LOGD ESTIMATING METHODS OF MARKED COMBINATORIAL LIBRARY COMPOUNDS
|
|
EP3359685B1
(en)
|
2015-10-09 |
2026-01-28 |
University Of Southampton |
Modulation of gene expression for deregulated protein expression
|
|
CN114686548A
(zh)
|
2015-10-14 |
2022-07-01 |
川斯勒佰尔公司 |
用于增强生产的rna相关酶的修饰
|
|
WO2017070151A1
(en)
|
2015-10-19 |
2017-04-27 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
|
|
IL307179A
(en)
|
2015-10-28 |
2023-11-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US20190046555A1
(en)
|
2015-11-06 |
2019-02-14 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds for use in therapy
|
|
AU2016349625B2
(en)
|
2015-11-06 |
2022-07-07 |
Ionis Pharmaceuticals, Inc. |
Modulating apolipoprotein (a) expression
|
|
US11058709B1
(en)
|
2015-12-04 |
2021-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
|
FI3386518T3
(fi)
|
2015-12-07 |
2025-09-25 |
Genzyme Corp |
Menetelmiä ja koostumuksia serpinc1:een liittyvän häiriön hoitamiseksi
|
|
WO2017100587A1
(en)
*
|
2015-12-09 |
2017-06-15 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting programmed cell death 1 ligand 1 (pd-l1) and methods of use thereof
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
EP3933041B1
(en)
|
2015-12-14 |
2024-01-31 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of autosomal dominant retardation
|
|
CA3005090A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of liver diseases
|
|
JP7054675B2
(ja)
|
2015-12-14 |
2022-04-14 |
コールド スプリング ハーバー ラボラトリー |
網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法
|
|
JP7049249B2
(ja)
|
2015-12-14 |
2022-04-06 |
コールド スプリング ハーバー ラボラトリー |
中枢神経系疾患の処置のための組成物および方法
|
|
CA3005245A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of alagille syndrome
|
|
WO2017106657A1
(en)
|
2015-12-18 |
2017-06-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
US20190002887A1
(en)
|
2015-12-31 |
2019-01-03 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing ataxin-2 expression
|
|
CA3006599A1
(en)
|
2016-01-05 |
2017-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing lrrk2 expression
|
|
AU2017213404A1
(en)
|
2016-01-29 |
2018-09-20 |
Kyowa Kirin Co., Ltd. |
Nucleic acid conjugate
|
|
WO2017132669A1
(en)
|
2016-01-31 |
2017-08-03 |
University Of Massachusetts |
Branched oligonucleotides
|
|
WO2017152149A1
(en)
|
2016-03-03 |
2017-09-08 |
University Of Massachusetts |
Closed-ended linear duplex dna for non-viral gene transfer
|
|
KR102515329B1
(ko)
*
|
2016-03-07 |
2023-03-29 |
애로우헤드 파마슈티컬스 인코포레이티드 |
치료용 화합물을 위한 표적화 리간드
|
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
|
AU2017234678A1
(en)
|
2016-03-16 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
|
WO2017173334A1
(en)
|
2016-04-01 |
2017-10-05 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
|
WO2017177169A1
(en)
|
2016-04-08 |
2017-10-12 |
Rana Therapeutics, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
SG10202008301UA
(en)
*
|
2016-04-11 |
2020-10-29 |
Arbutus Biopharma Corp |
Targeted nucleic acid conjugate compositions
|
|
EP3442983A1
(en)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE
|
|
CN110382692A
(zh)
|
2016-04-19 |
2019-10-25 |
博德研究所 |
新型crispr酶以及系统
|
|
MA45295A
(fr)
*
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
WO2017189996A1
(en)
*
|
2016-04-29 |
2017-11-02 |
Brandeis University |
Amino acid- and peptide-steroid conjugates and use thereof
|
|
SG10201913477UA
(en)
|
2016-04-29 |
2020-02-27 |
Univ Nanyang Tech |
G-quadruplex-containing antisense oligonucleotides
|
|
JP6872560B2
(ja)
|
2016-05-06 |
2021-05-19 |
エム． ウルフ、トッド |
プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法
|
|
EP3469083A1
(en)
*
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
|
CA3027312A1
(en)
|
2016-06-13 |
2017-12-21 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
|
|
EP3471781A4
(en)
|
2016-06-17 |
2020-05-06 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF GYS1 EXPRESSION
|
|
TWI746590B
(zh)
*
|
2016-06-30 |
2021-11-21 |
日商協和麒麟股份有限公司 |
核酸複合體
|
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
|
WO2018013525A1
(en)
|
2016-07-11 |
2018-01-18 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
|
ES2935658T3
(es)
|
2016-07-15 |
2023-03-09 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para la modulación de SMN2
|
|
IL291323B2
(en)
|
2016-07-15 |
2023-09-01 |
Am Chemicals Llc |
Solid non-nucleoside supports and phosphoramidite building blocks for oligonucleotide synthesis
|
|
JOP20190015A1
(ar)
|
2016-08-04 |
2019-02-04 |
Arrowhead Pharmaceuticals Inc |
عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
|
|
CA3033368A1
(en)
|
2016-08-12 |
2018-02-15 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
JP2019532027A
(ja)
|
2016-08-17 |
2019-11-07 |
ソルスティス バイオロジクス，リミティッド |
ポリヌクレオチド構築物
|
|
UY37376A
(es)
|
2016-08-26 |
2018-03-23 |
Amgen Inc |
Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
|
|
MX2018009853A
(es)
|
2016-09-02 |
2018-11-09 |
Arrowhead Pharmaceuticals Inc |
Ligandos de direccion.
|
|
KR101933767B1
(ko)
*
|
2016-09-05 |
2018-12-28 |
(의료)길의료재단 |
발기부전 환자를 위한 콘돔
|
|
EP3522898A4
(en)
*
|
2016-10-06 |
2020-05-27 |
Ionis Pharmaceuticals, Inc. |
METHOD FOR CONJUGATING OLIGOMERIC COMPOUNDS
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
TW202313978A
(zh)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
|
|
EP4035659A1
(en)
|
2016-11-29 |
2022-08-03 |
PureTech LYT, Inc. |
Exosomes for delivery of therapeutic agents
|
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
|
US10611823B2
(en)
|
2016-12-14 |
2020-04-07 |
Hanssen Biotech, Inc |
CD137 binding fibronectin type III domains
|
|
WO2018111976A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Pd-l1 binding fibronectin type iii domains
|
|
NZ754187A
(en)
|
2016-12-14 |
2026-02-27 |
Janssen Biotech Inc |
Cd8a-binding fibronectin type iii domains
|
|
AU2017376950B2
(en)
|
2016-12-16 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
|
|
IL267919B2
(en)
|
2017-01-09 |
2024-03-01 |
Aposense Ltd |
Compounds and methods for transmembrane transfer of molecules
|
|
BR112019014282A2
(pt)
|
2017-01-10 |
2020-03-03 |
Arrowhead Pharmaceuticals, Inc. |
Agentes de rnai de antitripsina (aat) alfa-1, composições incluindo agentes de rnai de aat, e métodos de uso
|
|
EA201991747A1
(ru)
|
2017-02-27 |
2020-06-04 |
Транслейт Био, Инк. |
НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
|
|
CN106986942B
(zh)
*
|
2017-02-28 |
2020-12-25 |
国药中生生物技术研究院有限公司 |
一种包含蝙蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用
|
|
US11963974B2
(en)
|
2017-03-10 |
2024-04-23 |
National Center For Child Health And Development |
Antisense oligonucleotide and composition for prevention or treatment of glycogen storage disease type Ia
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
WO2018181428A1
(ja)
*
|
2017-03-29 |
2018-10-04 |
塩野義製薬株式会社 |
核酸医薬及び多分岐脂質の複合体
|
|
JP7155239B2
(ja)
|
2017-04-05 |
2022-10-18 |
サイレンス・セラピューティクス・ゲーエムベーハー |
産物及び組成物
|
|
WO2019193144A1
(en)
|
2018-04-05 |
2019-10-10 |
Silence Therapeutics Gmbh |
siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND
|
|
EP3385272A1
(en)
*
|
2017-04-05 |
2018-10-10 |
Silence Therapeutics GmbH |
Further novel oligonucleotide-ligand conjugates
|
|
WO2018185253A1
(en)
*
|
2017-04-05 |
2018-10-11 |
Silence Therapeutics Gmbh |
Ligand modified double-stranded nucleic acids
|
|
WO2018191278A2
(en)
|
2017-04-11 |
2018-10-18 |
Arbutus Biopharma Corporation |
Targeted compositions
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
IL269927B2
(en)
|
2017-04-18 |
2025-04-01 |
Alnylam Pharmaceuticals Inc |
Methods of treating patients with hepatitis B virus infection
|
|
US11324820B2
(en)
|
2017-04-18 |
2022-05-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
|
|
WO2018195355A1
(en)
|
2017-04-19 |
2018-10-25 |
Rxi Pharmaceuticals Corporation |
Topical delivery of nucleic acid compounds
|
|
WO2018200943A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
MX2019013752A
(es)
|
2017-05-16 |
2020-07-20 |
Translate Bio Inc |
Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
|
|
US11273222B2
(en)
|
2017-05-26 |
2022-03-15 |
National Cerebral And Cardiovascular Center |
Antisense nucleic acid targeting PCSK9
|
|
JP7406793B2
(ja)
|
2017-06-23 |
2023-12-28 |
ユニバーシティー オブ マサチューセッツ |
２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
|
|
WO2019006455A1
(en)
|
2017-06-30 |
2019-01-03 |
Solstice Biologics, Ltd. |
AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
|
|
US10195286B2
(en)
*
|
2017-07-04 |
2019-02-05 |
Aposense Ltd. |
Compounds and methods for trans-membrane delivery of molecules
|
|
UY37803A
(es)
|
2017-07-10 |
2019-02-28 |
Genzyme Corp |
Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia
|
|
CA3069451A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals, Inc. |
Methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
AU2018301477A1
(en)
|
2017-07-13 |
2020-02-27 |
Alnylam Pharmaceuticals Inc. |
Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof
|
|
WO2019027999A1
(en)
*
|
2017-07-31 |
2019-02-07 |
Ohio State Innovation Foundation |
BIOMIMETIC NANOMATERIALS AND USES THEREOF
|
|
WO2019027009A1
(ja)
*
|
2017-08-02 |
2019-02-07 |
協和発酵キリン株式会社 |
核酸複合体
|
|
WO2019027015A1
(ja)
*
|
2017-08-02 |
2019-02-07 |
協和発酵キリン株式会社 |
核酸複合体
|
|
CA3073020A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
EP3668834B1
(en)
|
2017-08-17 |
2024-10-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11197884B2
(en)
|
2017-08-18 |
2021-12-14 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
|
SG11202001590RA
(en)
|
2017-08-25 |
2020-03-30 |
Stoke Therapeutics Inc |
Antisense oligomers for treatment of conditions and diseases
|
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
|
CA3075205A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
Stabilized hnf4a sarna compositions and methods of use
|
|
WO2019048645A1
(en)
*
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE
|
|
CN110168093B
(zh)
*
|
2017-09-12 |
2023-08-15 |
中科蓝华(广州)生物医药技术有限公司 |
一种转染细胞内寄生虫的试剂盒及其应用
|
|
MX2020001912A
(es)
|
2017-09-14 |
2020-03-24 |
Arrowhead Pharmaceuticals Inc |
Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso.
|
|
EP3682007A2
(en)
*
|
2017-09-14 |
2020-07-22 |
Janssen BioPharma, Inc. |
Galnac derivatives
|
|
KR20250046363A
(ko)
|
2017-09-19 |
2025-04-02 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
|
|
GB2610100B
(en)
|
2017-10-23 |
2023-08-16 |
Stoke Therapeutics Inc |
Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases
|
|
AU2018360697A1
(en)
|
2017-11-01 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
IL274611B2
(en)
|
2017-11-13 |
2024-10-01 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
|
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
JP7365052B2
(ja)
|
2017-12-01 |
2023-10-19 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
CN110945130B
(zh)
|
2017-12-01 |
2024-04-09 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2019105437A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CA3083968C
(en)
|
2017-12-01 |
2024-04-23 |
Suzhou Ribo Life Science Co., Ltd. |
Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
|
|
WO2019105435A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
AR113490A1
(es)
|
2017-12-12 |
2020-05-06 |
Amgen Inc |
CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
|
|
JP2021508491A
(ja)
|
2017-12-18 |
2021-03-11 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
高移動度グループボックス−１（ＨＭＧＢ１）ｉＲＮＡ組成物及びその使用方法
|
|
EP3727428A1
(en)
|
2017-12-20 |
2020-10-28 |
Translate Bio, Inc. |
Improved composition and methods for treatment of ornithine transcarbamylase deficiency
|
|
US11459564B2
(en)
|
2017-12-21 |
2022-10-04 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
CA3086485A1
(en)
|
2017-12-21 |
2019-06-27 |
Alnylam Pharmaceuticals, Inc. |
Chirally-enriched double-stranded rna agents
|
|
WO2019127004A1
(zh)
|
2017-12-26 |
2019-07-04 |
广州市锐博生物科技有限公司 |
修饰的寡核苷酸和可用于合成修饰的寡核苷酸的化合物
|
|
EP3732185B1
(en)
*
|
2017-12-29 |
2025-02-26 |
Suzhou Ribo Life Science Co., Ltd. |
Conjugates and preparation and use thereof
|
|
IL275773B2
(en)
|
2018-01-01 |
2025-07-01 |
Aposense Ltd |
Compounds and methods for trans-membrane delivery of molecules
|
|
WO2019140102A1
(en)
*
|
2018-01-10 |
2019-07-18 |
Translate Bio Ma, Inc. |
Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
|
|
BR112020014425A2
(pt)
|
2018-01-15 |
2020-12-29 |
Ionis Pharmaceuticals, Inc. |
Moduladores de expressão de dnm2
|
|
WO2019147743A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
AU2019218987B2
(en)
|
2018-02-12 |
2025-04-24 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
US12246031B2
(en)
|
2018-02-13 |
2025-03-11 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
|
CN112041439A
(zh)
|
2018-02-14 |
2020-12-04 |
深度基因组学公司 |
用于威尔森病的寡核苷酸疗法
|
|
EP3759127A4
(en)
|
2018-03-02 |
2022-03-30 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
CN111511915A
(zh)
|
2018-03-09 |
2020-08-07 |
第一三共株式会社 |
糖原病Ia型治疗药
|
|
CN110305137A
(zh)
*
|
2018-03-20 |
2019-10-08 |
鲁南制药集团股份有限公司 |
一种培美曲塞二钠中间体及其制备方法
|
|
CN110305135B
(zh)
*
|
2018-03-20 |
2022-02-22 |
鲁南制药集团股份有限公司 |
一种培美曲塞二钠中间体及其制备方法
|
|
CN110305134B
(zh)
*
|
2018-03-20 |
2022-02-22 |
鲁南制药集团股份有限公司 |
一种培美曲塞二钠中间体及其制备方法
|
|
CN110305136A
(zh)
*
|
2018-03-20 |
2019-10-08 |
鲁南制药集团股份有限公司 |
一种培美曲塞二钠中间体及其制备方法
|
|
US11661601B2
(en)
|
2018-03-22 |
2023-05-30 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating FMR1 expression
|
|
EP3550021A1
(en)
*
|
2018-04-05 |
2019-10-09 |
Silence Therapeutics GmbH |
Products and compositions for inhibiting expression of a target gene
|
|
WO2019193189A1
(en)
*
|
2018-04-05 |
2019-10-10 |
Silence Therapeutics Gmbh |
siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS
|
|
KR102890791B1
(ko)
|
2018-04-09 |
2025-11-24 |
체크메이트 파마슈티칼스, 인크. |
바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
|
|
CA3094020A1
(en)
|
2018-04-11 |
2019-10-17 |
Ionis Pharmaceuticals, Inc. |
Modulators of ezh2 expression
|
|
EP3775211B1
(en)
|
2018-04-12 |
2023-04-05 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
US12060558B2
(en)
|
2018-05-04 |
2024-08-13 |
Stoke Therapeutics, Inc. |
Methods and compositions for treatment of cholesteryl ester storage disease
|
|
WO2019217459A1
(en)
|
2018-05-07 |
2019-11-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
|
EP3790972A1
(en)
|
2018-05-08 |
2021-03-17 |
Regulus Therapeutics Inc. |
Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
|
|
SG11202010215TA
(en)
|
2018-05-09 |
2020-11-27 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing atxn3 expression
|
|
JP7438135B2
(ja)
|
2018-05-09 |
2024-02-26 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｆｘｉの発現を低下させるための化合物及び方法
|
|
TWI851574B
(zh)
|
2018-05-14 |
2024-08-11 |
美商阿尼拉製藥公司 |
血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
|
|
IL279102B2
(en)
*
|
2018-05-30 |
2024-10-01 |
Dtx Pharma Inc |
Lipid-modified nucleic acid compounds and methods
|
|
CA3103429A1
(en)
|
2018-06-14 |
2019-12-19 |
Don W. Cleveland |
Compounds and methods for increasing stmn2 expression
|
|
CN112638375A
(zh)
|
2018-06-15 |
2021-04-09 |
旗舰创业创新五公司 |
通过后细胞信号传导因子的调节来增加免疫活性
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
KR102059815B1
(ko)
|
2018-07-09 |
2019-12-27 |
삼성전기주식회사 |
안테나 기판 및 이를 포함하는 안테나 모듈
|
|
EP3823725A4
(en)
|
2018-07-17 |
2023-05-10 |
Aronora, Inc. |
METHODS FOR SAFELY REDUCING THROMBOPOIETIN
|
|
TW202019441A
(zh)
|
2018-07-20 |
2020-06-01 |
美商雷格勒斯治療公司 |
用於經口遞送寡核苷酸之方法
|
|
BR112021000308A2
(pt)
|
2018-07-25 |
2021-04-13 |
Ionis Pharmaceuticals, Inc. |
Compostos e métodos para redução da expressão de atxn2
|
|
US20210292768A1
(en)
|
2018-08-08 |
2021-09-23 |
Arcturus Therapeutics, Inc. |
Compositions and agents against nonalcoholic steatohepatitis
|
|
WO2020033899A1
(en)
|
2018-08-10 |
2020-02-13 |
University Of Massachusetts |
Modified oligonucleotides targeting snps
|
|
CA3106701A1
(en)
|
2018-08-13 |
2020-02-20 |
Alnylam Pharmaceuticals, Inc. |
Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
|
|
US11987792B2
(en)
|
2018-08-16 |
2024-05-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
|
US11918600B2
(en)
|
2018-08-21 |
2024-03-05 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
|
|
JP7627042B2
(ja)
|
2018-08-23 |
2025-02-05 |
ユニバーシティー オブ マサチューセッツ |
Ｏ－メチルリッチ完全安定化オリゴヌクレオチド
|
|
CA3108544A1
(en)
|
2018-08-24 |
2020-02-27 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
CA3105385A1
(en)
|
2018-09-18 |
2020-03-26 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
TWI856973B
(zh)
|
2018-09-19 |
2024-10-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
IL281615B2
(en)
|
2018-09-21 |
2026-01-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
WO2020069055A1
(en)
|
2018-09-28 |
2020-04-02 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
EP3862024A4
(en)
|
2018-09-30 |
2022-08-17 |
Suzhou Ribo Life Science Co., Ltd. |
SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE
|
|
GB201816554D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
JP7543259B2
(ja)
|
2018-10-18 |
2024-09-02 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
BR112021008967A2
(pt)
|
2018-11-15 |
2021-08-17 |
Ionis Pharmaceuticals, Inc. |
moduladores da expressão de irf5
|
|
MX2021005969A
(es)
|
2018-11-21 |
2021-09-14 |
Translate Bio Inc |
Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
|
|
SG11202103794QA
(en)
|
2018-11-21 |
2021-05-28 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing prion expression
|
|
EP3884051A2
(en)
|
2018-11-23 |
2021-09-29 |
Sanofi |
Novel rna compositions and methods for inhibiting angptl8
|
|
CA3121410C
(en)
*
|
2018-11-30 |
2023-08-08 |
Kylonova (Xiamen) Biopharma Co., Ltd. |
Drug containing liver targeting specific ligand and thyroid hormone receptor agonist
|
|
CA3121449A1
(en)
|
2018-11-30 |
2020-06-04 |
Kyowa Kirin Co., Ltd. |
Nucleic acid conjugate
|
|
WO2020117706A1
(en)
|
2018-12-03 |
2020-06-11 |
Triplet Therapeutics, Inc. |
Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
|
|
EP3894554A1
(en)
|
2018-12-10 |
2021-10-20 |
Amgen Inc. |
Chemically-modified rnai constructs and uses thereof
|
|
CN113166761B
(zh)
|
2018-12-10 |
2025-09-09 |
美国安进公司 |
用于抑制pnpla3表达的rnai构建体
|
|
US20220056455A1
(en)
|
2018-12-20 |
2022-02-24 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
|
EP3899024A4
(en)
|
2018-12-21 |
2023-05-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of hsd17b13 expression
|
|
US12496347B2
(en)
|
2018-12-28 |
2025-12-16 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
GB201821269D0
(en)
|
2018-12-28 |
2019-02-13 |
Nippon Shinyaku Co Ltd |
Myostatin signal inhibitor
|
|
CN111377985B
(zh)
*
|
2018-12-29 |
2023-11-10 |
苏州瑞博生物技术股份有限公司 |
化合物和缀合物及其制备方法和用途
|
|
MY202837A
(en)
|
2019-01-11 |
2024-05-24 |
Acuitas Therapeutics Inc |
Lipids for lipid nanoparticle delivery of active agents
|
|
KR20210116509A
(ko)
|
2019-01-16 |
2021-09-27 |
젠자임 코포레이션 |
Serpinc1 irna 조성물 및 그의 이용 방법
|
|
CN113330117B
(zh)
*
|
2019-01-18 |
2024-05-28 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN113614232A
(zh)
|
2019-01-18 |
2021-11-05 |
马萨诸塞大学 |
动态药代动力学修饰锚
|
|
SG11202107399WA
(en)
|
2019-01-31 |
2021-08-30 |
Ionis Pharmaceuticals Inc |
Modulators of yap1 expression
|
|
TW202540426A
(zh)
|
2019-02-27 |
2025-10-16 |
美商Ionis製藥公司 |
Malat1表現之調節劑
|
|
KR20210134003A
(ko)
|
2019-02-27 |
2021-11-08 |
스톡 테라퓨틱스, 인크. |
병태 및 질환의 치료를 위한 안티센스 올리고머
|
|
FI3947684T3
(fi)
|
2019-03-29 |
2025-05-27 |
Ionis Pharmaceuticals Inc |
Yhdisteitä ja menetelmiä ube3a-ats:n moduloimiseksi
|
|
EP3953473A1
(en)
|
2019-04-12 |
2022-02-16 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
JP2022532652A
(ja)
|
2019-05-17 |
2022-07-15 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
オリゴヌクレオチドの経口送達
|
|
JP7610268B2
(ja)
|
2019-05-22 |
2025-01-08 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、薬物組成物及び複合体ならびに調製方法と使用
|
|
WO2020233680A1
(zh)
|
2019-05-22 |
2020-11-26 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
WO2020233651A1
(zh)
|
2019-05-22 |
2020-11-26 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
AU2020280438B2
(en)
|
2019-05-22 |
2025-03-06 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
US20220315929A1
(en)
|
2019-05-24 |
2022-10-06 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof
|
|
CA3140233A1
(en)
|
2019-05-24 |
2020-12-03 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition and conjugate, preparation method and use
|
|
EP3978609A4
(en)
|
2019-05-24 |
2024-02-07 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
TW202111124A
(zh)
|
2019-05-30 |
2021-03-16 |
美商安進公司 |
用於抑制ｓｃａｐ表現之ｒｎａｉ構建體及其使用方法
|
|
MX2021015003A
(es)
|
2019-06-06 |
2022-01-24 |
Arrowhead Pharmaceuticals Inc |
Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd).
|
|
AU2020301419B2
(en)
|
2019-06-25 |
2026-03-19 |
Amgen Inc. |
Purification methods for carbohydrate-linked oligonucleotides
|
|
CN110218728A
(zh)
*
|
2019-06-28 |
2019-09-10 |
厦门甘宝利生物医药有限公司 |
一种新化合物及其应用
|
|
EP3956450B1
(en)
|
2019-07-26 |
2025-08-13 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4007812A1
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
|
|
MX2022001710A
(es)
|
2019-08-09 |
2022-05-10 |
Univ Massachusetts |
Oligonucleótidos modificados químicamente dirigidos a los snp.
|
|
WO2021030613A1
(en)
|
2019-08-13 |
2021-02-18 |
Amgen Inc. |
Rnai constructs for inhibiting slc30a8 expression and methods of use thereof
|
|
EP4013870A1
(en)
|
2019-08-13 |
2022-06-22 |
Alnylam Pharmaceuticals, Inc. |
Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
|
|
CN114585633A
(zh)
|
2019-08-19 |
2022-06-03 |
米纳治疗有限公司 |
寡核苷酸缀合物组合物和使用方法
|
|
US20220290156A1
(en)
|
2019-08-27 |
2022-09-15 |
Sanofi |
Compositions and methods for inhibiting pcsk9
|
|
TW202122093A
(zh)
|
2019-08-29 |
2021-06-16 |
大陸商蘇州瑞博生物技術股份有限公司 |
化合物、藥物綴合物、試劑盒及其用途
|
|
EP4025252A4
(en)
|
2019-09-03 |
2023-10-18 |
Arcturus Therapeutics, Inc. |
ASIALOGLYCOPROTEIN RECEPTOR-MEDIATED ADMINISTRATION OF THERAPEUTICALLY ACTIVE CONJUGATES
|
|
AU2020343255A1
(en)
|
2019-09-03 |
2022-03-24 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
|
WO2021049504A1
(ja)
|
2019-09-10 |
2021-03-18 |
第一三共株式会社 |
肝臓送達用ＧａｌＮＡｃ－オリゴヌクレオチドコンジュゲートおよび製造方法
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
EP4038189A1
(en)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
|
WO2021072330A1
(en)
|
2019-10-09 |
2021-04-15 |
Silverback Therapeutics, Inc. |
Galnac-tgfbr1 inhibitor conjugates for the treatment of liver diseases
|
|
WO2021076543A1
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Epcam binding fibronectin type iii domains
|
|
EP4045062A1
(en)
|
2019-10-14 |
2022-08-24 |
Astrazeneca AB |
Modulators of pnpla3 expression
|
|
CN114786682B
(zh)
|
2019-10-14 |
2024-07-16 |
Aro生物疗法公司 |
结合cd71的纤维粘连蛋白iii型结构域
|
|
WO2021076574A2
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Fn3 domain-sirna conjugates and uses thereof
|
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
|
TW202134435A
(zh)
|
2019-10-22 |
2021-09-16 |
美商阿尼拉製藥公司 |
補體成分ｃ３ ｉｒｎａ組成物及其使用方法
|
|
CN119499394A
(zh)
|
2019-11-01 |
2025-02-25 |
阿尔尼拉姆医药品有限公司 |
亨廷顿（HTT）iRNA药剂组合物及其使用方法
|
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
EP4055165A1
(en)
|
2019-11-06 |
2022-09-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
CA3160329A1
(en)
*
|
2019-11-06 |
2021-05-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
|
KR20220115946A
(ko)
|
2019-11-13 |
2022-08-19 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐 (agt) 관련 장애를 치료하기 위한 방법 및 조성물
|
|
WO2021102356A1
(en)
|
2019-11-20 |
2021-05-27 |
Berg Llc |
Combination therapy of a coenzyme q10 compound and radiation therapy for treatment of glioma
|
|
WO2021102373A1
(en)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
|
US20230078200A1
(en)
|
2019-12-09 |
2023-03-16 |
Amgen Inc. |
RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
|
|
CN115175685B
(zh)
|
2019-12-09 |
2024-12-13 |
艾姆皮瑞克公司 |
用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸
|
|
EP4073251A1
(en)
|
2019-12-13 |
2022-10-19 |
Alnylam Pharmaceuticals, Inc. |
Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
|
|
TW202138559A
(zh)
|
2019-12-16 |
2021-10-16 |
美商阿尼拉製藥公司 |
含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
|
|
CN111041025B
(zh)
|
2019-12-17 |
2021-06-18 |
深圳市瑞吉生物科技有限公司 |
基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法
|
|
JP2023509359A
(ja)
|
2019-12-17 |
2023-03-08 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
鉄依存性細胞分解の誘導物質との併用抗癌療法
|
|
EP4071163A4
(en)
|
2020-01-30 |
2024-03-20 |
Eisai R&D Management Co., Ltd. |
NUCLEIC ACID COMPLEX AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
MX2022009763A
(es)
|
2020-02-10 |
2022-09-09 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para silenciar la expresion del factor de crecimiento endotelial vascular a (vegf-a).
|
|
KR20220143106A
(ko)
|
2020-02-18 |
2022-10-24 |
알닐람 파마슈티칼스 인코포레이티드 |
아포지질단백질 C3 (APOC3) iRNA 조성물 및 이의 사용 방법
|
|
CR20220485A
(es)
|
2020-02-28 |
2022-11-10 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular smn2
|
|
KR20230011913A
(ko)
|
2020-03-04 |
2023-01-25 |
버브 테라퓨틱스, 인크. |
표적화된 rna 전달을 위한 조성물 및 방법
|
|
WO2021178607A1
(en)
|
2020-03-05 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
|
BR112022017822A2
(pt)
|
2020-03-06 |
2022-11-08 |
Alnylam Pharmaceuticals Inc |
Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas
|
|
KR20220152270A
(ko)
|
2020-03-06 |
2022-11-15 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴 (ttr)의 발현을 억제하기 위한 조성물 및 방법
|
|
EP4121534A1
(en)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
|
EP4126967A1
(en)
|
2020-03-23 |
2023-02-08 |
Amgen Inc. |
Monoclonal antibodies to chemically-modified nucleic acids and uses thereof
|
|
AU2021244559A1
(en)
|
2020-03-24 |
2022-11-17 |
Generation Bio Co. |
Non-viral DNA vectors and uses thereof for expressing Gaucher therapeutics
|
|
MX2022011805A
(es)
|
2020-03-24 |
2023-01-11 |
Generation Bio Co |
Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix.
|
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
|
EP4127171A2
(en)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
WO2021202902A1
(en)
|
2020-04-01 |
2021-10-07 |
Alnylam Pharmaceuticals, Inc. |
ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4133078A1
(en)
|
2020-04-06 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
|
EP4133076A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
|
|
CA3179678A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
|
US12194157B2
(en)
|
2020-04-09 |
2025-01-14 |
Finncure Oy |
Carrier for targeted delivery to a host
|
|
EP4132478A1
(en)
|
2020-04-09 |
2023-02-15 |
Finncure Oy |
Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
|
|
AU2021260934A1
(en)
|
2020-04-21 |
2022-11-24 |
Flagship Pioneering, Inc. |
Bifunctional molecules and methods of using thereof
|
|
KR20230018377A
(ko)
|
2020-04-27 |
2023-02-07 |
알닐람 파마슈티칼스 인코포레이티드 |
아포지질단백질 e (apoe) irna 제제 조성물 및 이의 사용 방법
|
|
CN113563414B
(zh)
*
|
2020-04-29 |
2022-08-12 |
泰比棣医药科技(石家庄)有限公司 |
一种组织靶向的蛋白靶向降解化合物及其用途
|
|
MX2022013606A
(es)
|
2020-04-30 |
2023-01-16 |
Alnylam Pharmaceuticals Inc |
Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
|
|
MX2022013707A
(es)
|
2020-05-01 |
2022-12-07 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular atxn1.
|
|
BR112022022889A2
(pt)
|
2020-05-11 |
2023-04-04 |
Stoke Therapeutics Inc |
Oligômeros antissentido de opa1 para tratamento de condições e doenças
|
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
EP4150089A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
|
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
EP4150078A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
CN113683651A
(zh)
*
|
2020-05-19 |
2021-11-23 |
上海京新生物医药有限公司 |
一种GalNAc中间体的制备方法
|
|
WO2021237097A1
(en)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
JP2023526533A
(ja)
|
2020-05-22 |
2023-06-21 |
ウェイブ ライフ サイエンシズ リミテッド |
二本鎖オリゴヌクレオチド組成物及びそれに関連する方法
|
|
WO2021242883A1
(en)
|
2020-05-26 |
2021-12-02 |
University Of Massachusetts |
Synthetic oligonucleotides having regions of block and cluster modifications
|
|
MX2022015169A
(es)
|
2020-06-01 |
2023-07-03 |
Amgen Inc |
Constructos de arni para inhibir la expresion de hsd17b13 y metodos de uso de los mismos.
|
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
|
CN116075592A
(zh)
|
2020-06-09 |
2023-05-05 |
阿尔尼拉姆医药品有限公司 |
用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法
|
|
WO2021252557A1
(en)
|
2020-06-09 |
2021-12-16 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
|
TW202214856A
(zh)
|
2020-06-18 |
2022-04-16 |
美商阿尼拉製藥公司 |
黃嘌呤脫氫酶（ＸＤＨ）ｉＲＮＡ組成物及其使用之方法
|
|
JP2023532339A
(ja)
|
2020-06-29 |
2023-07-27 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
|
|
BR112022024206A2
(pt)
|
2020-06-29 |
2023-01-03 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para modular plp1
|
|
CN111744019B
(zh)
*
|
2020-07-01 |
2023-08-04 |
深圳瑞吉生物科技有限公司 |
基于甘露糖的mRNA靶向递送系统及其应用
|
|
US20230257745A1
(en)
|
2020-07-10 |
2023-08-17 |
Alnylam Pharmaceuticals, Inc. |
Circular siRNAs
|
|
KR20230050336A
(ko)
|
2020-07-10 |
2023-04-14 |
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) |
뇌전증을 치료하기 위한 방법과 조성물
|
|
WO2022016070A1
(en)
|
2020-07-16 |
2022-01-20 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
AU2021315992A1
(en)
|
2020-07-28 |
2023-02-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing app expression
|
|
IL300258A
(en)
|
2020-08-07 |
2023-03-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating SCN2A
|
|
PE20230993A1
(es)
|
2020-08-13 |
2023-06-23 |
Amgen Inc |
Construcciones de iarn y metodos para inhibir la expresion de marc1
|
|
CN116583303A
(zh)
*
|
2020-08-21 |
2023-08-11 |
瑞阳公司 |
雷公藤甲素缀合物和其用途
|
|
AU2021342158A1
(en)
*
|
2020-09-11 |
2023-04-13 |
Arrowhead Pharmaceuticals, Inc. |
Lipid conjugates for the delivery of therapeutic agents
|
|
CZ310613B6
(cs)
|
2020-09-23 |
2026-01-28 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
EP4217489A1
(en)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
|
JP2023544413A
(ja)
|
2020-10-05 |
2023-10-23 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
Ｇタンパク質共役受容体７５（ＧＰＲ７５）ｉＲＮＡ組成物およびその使用方法
|
|
US20240035029A1
(en)
|
2020-10-16 |
2024-02-01 |
Sanofi |
Rna compositions and methods for inhibiting lipoprotein(a)
|
|
JP2023546103A
(ja)
|
2020-10-16 |
2023-11-01 |
サノフイ |
Ａｎｇｐｔｌ３を阻害するための新規のｒｎａ組成物および方法
|
|
EP4232581A1
(en)
|
2020-10-21 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
|
EP4232582A1
(en)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
|
WO2022098841A1
(en)
|
2020-11-05 |
2022-05-12 |
Amgen Inc. |
METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
|
|
KR20230107625A
(ko)
|
2020-11-13 |
2023-07-17 |
알닐람 파마슈티칼스 인코포레이티드 |
응고 인자 V(F5) iRNA 조성물 및 이의 사용 방법
|
|
EP4136092B1
(en)
|
2020-11-18 |
2024-07-31 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
|
WO2022119873A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
WO2022125490A1
(en)
|
2020-12-08 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
|
JP2023554346A
(ja)
|
2020-12-18 |
2023-12-27 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
第ｘｉｉ因子を調節するための化合物及び方法
|
|
CN117015386A
(zh)
|
2020-12-21 |
2023-11-07 |
旗舰创业创新五公司 |
细胞周转因子用于增加组织再生的用途
|
|
IL303886A
(en)
|
2020-12-23 |
2023-08-01 |
Flagship Pioneering Inc |
Compositions of modified trems and uses thereof
|
|
EP4273245A4
(en)
|
2020-12-29 |
2024-12-11 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND SIRNA CONJUGATE WITH THE NUCLEIC ACID, MANUFACTURING PROCESS THEREOF AND USE THEREOF
|
|
EP4274896A1
(en)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component 9 (c9) irna compositions and methods of use thereof
|
|
WO2022172083A2
(en)
*
|
2021-01-21 |
2022-08-18 |
Sirnaomics, Inc. |
Targeted nucleic acid therapy for hepatitis b
|
|
US20230390411A1
(en)
*
|
2021-01-28 |
2023-12-07 |
Nanjing Chempion Biotechnology Co., Ltd. |
Conjugate and use thereof
|
|
CA3204340A1
(en)
*
|
2021-01-30 |
2022-08-04 |
Ahmad Ali MORTAZAVI |
Conjugated oligonucleotide compounds, methods of making and uses thereof
|
|
EP4175964A1
(en)
*
|
2021-01-30 |
2023-05-10 |
E-Therapeutics plc |
Conjugated oligonucleotide compounds, methods of making and uses thereof
|
|
WO2022174000A2
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
CN117222739A
(zh)
|
2021-02-25 |
2023-12-12 |
阿尔尼拉姆医药品有限公司 |
朊病毒蛋白(prnp)irna组合物和其使用方法
|
|
TW202302847A
(zh)
|
2021-02-26 |
2023-01-16 |
美商艾拉倫製藥股份有限公司 |
己酮糖激酶（ＫＨＫ）ｉＲＮＡ組成物及其使用方法
|
|
IL305442A
(en)
|
2021-03-04 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
|
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
|
CA3207897A1
(en)
|
2021-03-19 |
2022-09-22 |
Ralf Eisenhuth |
Improved oligonucleotide synthesis
|
|
EP4316495A4
(en)
*
|
2021-03-25 |
2025-12-31 |
Aptacure Therapeutics Ltd |
CONJUGATE OF NUCLEIC ACID MOLECULE HAVING A PROLONGED IN VIVO HALF-LIFE
|
|
EP4314292A1
(en)
|
2021-03-26 |
2024-02-07 |
MiNA Therapeutics Limited |
Tmem173 sarna compositions and methods of use
|
|
WO2022212231A2
(en)
|
2021-03-29 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
|
JP2024512669A
(ja)
|
2021-03-31 |
2024-03-19 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
|
|
EP4314293A1
(en)
|
2021-04-01 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
|
WO2022216841A1
(en)
|
2021-04-06 |
2022-10-13 |
Berg Llc |
Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
|
|
EP4320443A1
(en)
|
2021-04-06 |
2024-02-14 |
BPGbio, Inc. |
Protein markers for the prognosis of breast cancer progression
|
|
EP4320441A1
(en)
|
2021-04-06 |
2024-02-14 |
BPGbio, Inc. |
Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
|
|
CN117304473A
(zh)
*
|
2021-04-08 |
2023-12-29 |
厦门赛诺邦格生物科技股份有限公司 |
一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
|
|
CN115197080A
(zh)
*
|
2021-04-08 |
2022-10-18 |
厦门赛诺邦格生物科技股份有限公司 |
一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
|
|
US20250282813A1
(en)
|
2021-04-09 |
2025-09-11 |
Bachem Holding Ag |
Pseudo solid phase protecting group and methods for the synthesis of oligonucleotides and oligonucleotide conjugates
|
|
CA3214552A1
(en)
|
2021-04-14 |
2022-10-20 |
Russell C. Addis |
Cd71 binding fibronectin type iii domains
|
|
BR112023021318A2
(pt)
|
2021-04-14 |
2023-12-19 |
Aro Biotherapeutics Company |
Conjugados de domínio fn3-sirna e usos dos mesmos
|
|
AU2022262794A1
(en)
|
2021-04-23 |
2023-11-02 |
Beth Israel Deaconess Medical Center, Inc. |
Glycan modified nucleic acids, methods of preparation, and therapeutic uses
|
|
MX2023012586A
(es)
|
2021-04-26 |
2023-10-31 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) de serina 6, proteasa transmembranaria (tmprss6) y sus metodos de uso.
|
|
BR112023022439A2
(pt)
|
2021-04-26 |
2023-12-26 |
Celanese Eva Performance Polymers Llc |
Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
|
|
CN117881786A
(zh)
|
2021-04-27 |
2024-04-12 |
世代生物公司 |
表达治疗性抗体的非病毒dna载体及其用途
|
|
EP4329884A1
(en)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
JP2024519293A
(ja)
|
2021-04-29 |
2024-05-10 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
シグナル伝達兼転写活性化因子６（ＳＴＡＴ６）ｉＲＮＡ組成物およびその使用方法
|
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
EP4347823A1
(en)
|
2021-06-02 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
CN117561334A
(zh)
|
2021-06-04 |
2024-02-13 |
阿尔尼拉姆医药品有限公司 |
人染色体9开放阅读框72（C9ORF72）iRNA药剂组合物和其使用方法
|
|
EP4351541A2
(en)
|
2021-06-08 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
|
KR20240023602A
(ko)
|
2021-06-18 |
2024-02-22 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Ifnar1 발현을 감소시키기 위한 화합물 및 방법
|
|
CN115572241B
(zh)
*
|
2021-06-21 |
2024-08-30 |
润佳（苏州）医药科技有限公司 |
双价化合物、偶联物及其用途
|
|
CA3224904A1
(en)
|
2021-06-21 |
2022-12-29 |
Shanghai Junshi Biosciences Co., Ltd. |
Sirna inhibiting angptl3 gene expression and use thereof
|
|
AU2022299169A1
(en)
|
2021-06-23 |
2024-02-08 |
Beth Israel Deaconess Medical Center, Inc. |
Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
|
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
US20240316104A1
(en)
|
2021-06-29 |
2024-09-26 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
IL309296A
(en)
|
2021-06-30 |
2024-02-01 |
Alnylam Pharmaceuticals Inc |
Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
|
|
US20240285547A1
(en)
|
2021-07-08 |
2024-08-29 |
Nippon Shinyaku Co., Ltd. |
Nephrotoxicity reducing agent
|
|
US20240285770A1
(en)
|
2021-07-08 |
2024-08-29 |
Nippon Shinyaku Co., Ltd. |
Precipitation suppressing agent
|
|
CN118475355A
(zh)
|
2021-07-08 |
2024-08-09 |
日本新药株式会社 |
肾毒性减轻剂
|
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
|
CN117580953B
(zh)
|
2021-07-16 |
2025-07-18 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
US20240309378A1
(en)
|
2021-07-16 |
2024-09-19 |
Suzhou Ribo Life Science Co., Ltd. |
Double-stranded oligonucleotide, composition and conjugate containing double-stranded oligonucleotide, and preparation methods and uses
|
|
WO2023003805A1
(en)
|
2021-07-19 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
|
CZ310443B6
(cs)
|
2021-07-19 |
2025-06-25 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
TW202421169A
(zh)
|
2021-07-21 |
2024-06-01 |
美商艾拉倫製藥股份有限公司 |
代謝疾患相關的標靶基因ｉＲＮＡ組成物及其使用方法
|
|
CA3226878A1
(en)
|
2021-07-23 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
|
JP2024529437A
(ja)
|
2021-07-29 |
2024-08-06 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
３－ヒドロキシ－３－メチルグリタル－ＣＯＡレダクターゼ（ＨＭＧＣＲ）ｉＲＮＡ組成物およびその使用方法
|
|
CN115920065A
(zh)
*
|
2021-08-02 |
2023-04-07 |
南方科技大学 |
一种可靶向去唾液酸糖蛋白受体的配体及其缀合物与用途
|
|
JP2024530647A
(ja)
*
|
2021-08-03 |
2024-08-23 |
ヴァーヴ・セラピューティクス，インコーポレーテッド |
標的ｒｎａ送達のための組成物および方法
|
|
CA3227852A1
(en)
|
2021-08-03 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
|
JP2024528270A
(ja)
*
|
2021-08-04 |
2024-07-26 |
ヘパジーン セラピューティクス（エイチケー）リミティド |
治療活性剤の送達のためのリガンド共役体
|
|
IL310295A
(en)
|
2021-08-04 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
iRNA compositions and methods for silencing angiotensinogen (AGT)
|
|
AU2022324471A1
(en)
|
2021-08-05 |
2024-02-15 |
Sanegene Bio Usa Inc. |
1'-alkyl modified ribose derivatives and methods of use
|
|
CN117858883A
(zh)
|
2021-08-09 |
2024-04-09 |
莱尔纳生物制药私人有限公司 |
GalNAc单体和GalNAc寡核苷酸缀合物
|
|
KR20240045300A
(ko)
|
2021-08-13 |
2024-04-05 |
알닐람 파마슈티칼스 인코포레이티드 |
인자 XII (F12) iRNA 조성물 및 이의 사용 방법
|
|
WO2023034837A2
(en)
|
2021-08-31 |
2023-03-09 |
Alnylam Pharmaceuticals, Inc. |
Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof
|
|
WO2023039594A1
(en)
*
|
2021-09-13 |
2023-03-16 |
Ganna Bio, Inc. |
Glycan conjugate compositions and methods
|
|
JP2024535850A
(ja)
|
2021-09-17 |
2024-10-02 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
|
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
|
EP4405368A1
(en)
|
2021-09-22 |
2024-07-31 |
Sanegene Bio USA Inc. |
2'-alkyl or 3'- alkyl modified ribose derivatives for use in the in-vivo delivery of oligonucleotides
|
|
KR20240067943A
(ko)
|
2021-09-24 |
2024-05-17 |
알닐람 파마슈티칼스 인코포레이티드 |
미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법
|
|
MX2024004011A
(es)
|
2021-10-01 |
2024-07-01 |
Adarx Pharmaceuticals Inc |
Composiciones moduladoras de precalicreína y métodos de uso de estas.
|
|
CN118076621A
(zh)
|
2021-10-05 |
2024-05-24 |
美国圣因生物股份有限公司 |
多羟基化的环戊烷衍生物及使用方法
|
|
CN118556125A
(zh)
|
2021-10-05 |
2024-08-27 |
美国安进公司 |
用于增强寡核苷酸化合物的基因沉默活性的组合物和方法
|
|
WO2023064891A1
(en)
|
2021-10-14 |
2023-04-20 |
Hemoshear Therapeutics, Inc. |
Compositions and methods of treating diseases associated with bile acid transporter
|
|
MX2024004437A
(es)
|
2021-10-15 |
2024-07-01 |
Alnylam Pharmaceuticals Inc |
Composiciones de inhibidor de la angiotensina-receptor neprilisina (arni) de administracion extrahepatica y metodos de uso de las mismas.
|
|
CA3235262A1
(en)
|
2021-10-22 |
2023-04-27 |
Amgen Inc. |
Rnai constructs for inhibiting gpam expression and methods of use thereof
|
|
US20250352667A1
(en)
|
2021-10-22 |
2025-11-20 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
TW202333749A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
補體因子ｂ（ｃｆｂ）ｉｒｎａ組成物及其使用方法
|
|
WO2023076450A2
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
US20250066790A1
(en)
|
2021-11-10 |
2025-02-27 |
University Of Rochester |
Antisense oligonucleotides for modifying protein expression
|
|
US20250019702A1
(en)
|
2021-11-10 |
2025-01-16 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
EP4471140A1
(en)
|
2022-01-30 |
2024-12-04 |
Rona Bioscience, Limited |
Targeting ligand containing n-acetylgalactosamine
|
|
IL314850A
(en)
|
2022-02-22 |
2024-10-01 |
Sanegene Bio Usa Inc |
Ribonucleotide derivatives substituted at the 5' position in the carboxyl group and methods of use
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
CN120129745A
(zh)
|
2022-03-10 |
2025-06-10 |
日本新药株式会社 |
抗病毒反义低聚物
|
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
|
EP4493570A2
(en)
|
2022-03-16 |
2025-01-22 |
Empirico Inc. |
Galnac compositions for improving sirna bioavailability
|
|
JPWO2023176863A1
(https=)
|
2022-03-16 |
2023-09-21 |
|
|
|
KR20240161967A
(ko)
|
2022-03-16 |
2024-11-13 |
다이이찌 산쿄 가부시키가이샤 |
트랜스페린 수용체 2 의 발현을 억제하는 siRNA
|
|
KR20240163743A
(ko)
|
2022-03-28 |
2024-11-19 |
엠피리코 인크. |
변형된 올리고뉴클레오티드
|
|
CN119213006A
(zh)
*
|
2022-04-26 |
2024-12-27 |
康涅狄格大学 |
用于增强肝脏和肾脏特异性靶向的遗传序列-糖缀合物
|
|
US20240002857A1
(en)
|
2022-05-09 |
2024-01-04 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof
|
|
EP4522742A2
(en)
|
2022-05-13 |
2025-03-19 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
|
US20230372508A1
(en)
|
2022-05-19 |
2023-11-23 |
Olix Us, Inc. |
Linkers coupling functional ligands to macromolecules
|
|
JP2025520520A
(ja)
*
|
2022-06-14 |
2025-07-03 |
大睿生物 |
ＰＣＳＫ９遺伝子活性を調節するｓｉＲＮＡ分子
|
|
WO2023241587A1
(zh)
|
2022-06-14 |
2023-12-21 |
大睿生物医药科技(上海)有限公司 |
环膦酸酯修饰的核苷酸
|
|
US20250179492A1
(en)
|
2022-06-22 |
2025-06-05 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
JP2025520796A
(ja)
|
2022-06-27 |
2025-07-03 |
大睿生物 |
アポリポタンパク質Ｃ３発現を阻害するｓｉＲＮＡ
|
|
CN119487192A
(zh)
*
|
2022-06-27 |
2025-02-18 |
中美瑞康核酸技术(南通)研究院有限公司 |
小激活核酸分子及其在治疗遗传性血管性水肿中的用途
|
|
IL317824A
(en)
|
2022-07-11 |
2025-02-01 |
Sanegene Bio Usa Inc |
Ribose derivatives modified at the '2' position and methods of use
|
|
IL317825A
(en)
|
2022-07-25 |
2025-02-01 |
Amgen Inc |
RNA interference constructs and methods for inhibiting fam13a expression
|
|
KR20250046303A
(ko)
|
2022-08-05 |
2025-04-02 |
사네진 바이오 유에스에이 인크. |
안지오텐시노겐 (agt)을 표적화하는 이중 가닥 rna 및 그의 사용 방법
|
|
JP2025527531A
(ja)
|
2022-08-18 |
2025-08-22 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
ユニバーサル非標的ｓｉｒｎａ組成物およびその使用方法
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
EP4581143A1
(en)
|
2022-08-29 |
2025-07-09 |
University of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
|
JP2025532593A
(ja)
|
2022-09-15 |
2025-10-01 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
１７ｂ－ヒドロキシステロイドデヒドロゲナーゼ１３型（ｈｓｄ１７ｂ１３）ｉｒｎａ組成物およびその使用方法
|
|
US20260001902A1
(en)
|
2022-09-19 |
2026-01-01 |
Bachem Holding Ag |
Improved oligonucleotide synthesis
|
|
JP2025532127A
(ja)
|
2022-09-23 |
2025-09-29 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｍｅｃｐ２発現を低減する化合物及び方法
|
|
JP2025533501A
(ja)
|
2022-09-28 |
2025-10-07 |
サレプタ セラピューティクス， インコーポレイテッド |
ポンペ病マウスモデルの生成、特徴決定および使用方法
|
|
JP2025532985A
(ja)
|
2022-09-30 |
2025-10-03 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
修飾二本鎖ｒｎａ剤
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
CN120265773A
(zh)
|
2022-10-14 |
2025-07-04 |
美国圣因生物股份有限公司 |
靶向c3的小干扰rna及其用途
|
|
WO2024083746A1
(en)
|
2022-10-17 |
2024-04-25 |
Bachem Holding Ag |
Method and composition for oligonucleotide synthesis
|
|
CN120225676A
(zh)
|
2022-12-02 |
2025-06-27 |
上海舶望制药有限公司 |
双环脱碱基核酸类似物以及由它们制备的寡聚化合物
|
|
EP4630061A1
(en)
*
|
2022-12-08 |
2025-10-15 |
Nanovation Therapeutics Inc. |
Lipid nanoparticles comprising elevated neutral lipid and a targeting moiety for targeted delivery of nucleic acid
|
|
WO2024129710A1
(en)
*
|
2022-12-12 |
2024-06-20 |
University Of Massachusetts |
Carbohydrate conjugates for the delivery of therapeutic oligonucleotides
|
|
AR131389A1
(es)
|
2022-12-16 |
2025-03-12 |
Amgen Inc |
CONSTRUCTOS DE ARNi PARA INHIBIR LA EXPRESIÓN DE TTR Y MÉTODOS DE USO DE LOS MISMOS
|
|
AU2023408479A1
(en)
|
2022-12-19 |
2025-05-01 |
Arnatar Therapeutics, Inc |
Advanced rna targeting (arnatar)
|
|
EP4638743A2
(en)
|
2022-12-19 |
2025-10-29 |
Sanegene Bio USA Inc. |
Small interfering rna targeting cfb and uses thereof
|
|
EP4592432A3
(en)
|
2022-12-19 |
2025-10-29 |
Arnatar Therapeutics |
Arnatar compounds and methods for enhanced cellular uptake
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
CN117720590A
(zh)
*
|
2022-12-30 |
2024-03-19 |
天津药明康德新药开发有限公司 |
一种改进的n-乙酰半乳糖胺中间体的制备方法
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
US20240254485A1
(en)
|
2023-01-13 |
2024-08-01 |
Hemoshear Therapeutics, Inc. |
Sirnas targeting slc10a1 transcripts, compositions and uses thereof
|
|
EP4662311A2
(en)
|
2023-02-09 |
2025-12-17 |
Alnylam Pharmaceuticals, Inc. |
Reversir molecules and methods of use thereof
|
|
US20240309383A1
(en)
|
2023-02-24 |
2024-09-19 |
Suzhou Sanegene Bio Inc. |
Small interfering rna targeting hbv and uses thereof
|
|
WO2024186673A2
(en)
|
2023-03-03 |
2024-09-12 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting apoc3 and uses thereof
|
|
WO2024188174A1
(zh)
|
2023-03-10 |
2024-09-19 |
苏州瑞博生物技术股份有限公司 |
一种药物组合物及其用途
|
|
WO2024206230A1
(en)
*
|
2023-03-24 |
2024-10-03 |
Trustees Of Tufts College |
Tissue targeting lipids and lipid nanoparticles
|
|
AU2024259356A1
(en)
*
|
2023-04-19 |
2025-11-06 |
Prime Medicine, Inc. |
Lipid nanoparticle (lnp) delivery systems and formulations
|
|
WO2024220930A2
(en)
|
2023-04-20 |
2024-10-24 |
Adarx Pharmaceuticals, Inc. |
Mapt-modulating compositions and methods of use thereof
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
KR20260005960A
(ko)
|
2023-05-03 |
2026-01-12 |
사네진 바이오 유에스에이 인크. |
전신, 중추 신경계, 말초 신경계, 및 안구 전달을 위한 지질 기반 접합체
|
|
AU2024269205A1
(en)
|
2023-05-11 |
2025-12-11 |
Keymed Biosciences (Us) Inc. |
Dsrna molecules for regulating masp2 gene activity
|
|
AU2024269116A1
(en)
|
2023-05-11 |
2025-11-20 |
Sunshine Lake Pharma Co., Ltd. |
Novel targeting compound and use thereof, and nucleic acid conjugate and use thereof
|
|
CN121398851A
(zh)
|
2023-05-12 |
2026-01-23 |
阿达尔克斯制药有限公司 |
Nmda配体缀合的化合物及其用途
|
|
WO2024238385A2
(en)
|
2023-05-12 |
2024-11-21 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
|
CN118993970B
(zh)
*
|
2023-05-17 |
2025-12-23 |
苏州富士莱医药股份有限公司 |
一种l96侧链化合物的制备方法
|
|
WO2024240212A1
(zh)
|
2023-05-24 |
2024-11-28 |
云合智药（苏州）生物科技有限公司 |
用于抑制angptl3表达的rnai剂及其应用
|
|
IL324720A
(en)
|
2023-05-26 |
2026-01-01 |
Adarx Pharmaceuticals Inc |
SOD1 modulators and methods of using them
|
|
WO2024249889A1
(en)
*
|
2023-05-31 |
2024-12-05 |
University Of Connecticut |
Genetic sequence/small molecule-carbohydrate conjugates for enhanced lung-specific targeting
|
|
EP4562158A1
(en)
|
2023-06-13 |
2025-06-04 |
Arnatar Therapeutics, Inc |
Advanced rna targeting (arnatar) for angiotensinogen
|
|
CN121712891A
(zh)
|
2023-06-20 |
2026-03-20 |
阿达尔克斯制药有限公司 |
Lrrk2调节组合物及其使用方法
|
|
CN121866332A
(zh)
|
2023-06-21 |
2026-04-14 |
美国圣因生物股份有限公司 |
靶向前蛋白转化酶枯草杆菌蛋白酶kexin 9（pcsk9）的双链rna及其使用方法
|
|
US12508320B2
(en)
|
2023-06-29 |
2025-12-30 |
SeeCure Taiwan Co., Ltd. |
Drug conjugate, pharmaceutical composition and method of treating hepatitis
|
|
WO2025002208A1
(zh)
*
|
2023-06-30 |
2025-01-02 |
苏州时安生物技术有限公司 |
一种核酸缀合物、制备方法及用途
|
|
CN121399258A
(zh)
|
2023-07-06 |
2026-01-23 |
大睿生物医药科技(上海)有限公司 |
调控AGT表达的dsRNA分子
|
|
AU2024287308A1
(en)
|
2023-07-13 |
2025-12-18 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
WO2025015338A1
(en)
|
2023-07-13 |
2025-01-16 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
TW202517784A
(zh)
|
2023-07-14 |
2025-05-01 |
大陸商云合智藥（蘇州）生物科技有限公司 |
用於抑制己酮糖激酶表達的ＲＮＡｉ劑及其應用
|
|
GB202311324D0
(en)
|
2023-07-24 |
2023-09-06 |
Astrazeneca Ab |
Multivalent cargo-carrying complexes and uses thereof
|
|
GB202311334D0
(en)
|
2023-07-24 |
2023-09-06 |
Astrazeneca Ab |
Multivalent cargo-carrying complexes and uses thereof
|
|
US20250051771A1
(en)
|
2023-07-24 |
2025-02-13 |
Astrazeneca Ab |
Multivalent cargo-carrying complexes and uses thereof
|
|
US20250064939A1
(en)
|
2023-07-24 |
2025-02-27 |
Sanegene Bio Usa Inc. |
Lipid-based enhancement agent for rna delivery and therapy
|
|
AU2024321710A1
(en)
|
2023-08-04 |
2026-03-05 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Double-stranded ribonucleic acid targeting pd-l1
|
|
KR20260049597A
(ko)
|
2023-08-04 |
2026-04-14 |
알닐람 파마슈티칼스 인코포레이티드 |
Ctnnb1-관련 질환을 치료하기 위한 방법 및 조성물
|
|
AU2024321098A1
(en)
|
2023-08-09 |
2026-03-19 |
Beijing Foyou Pharma Co., Ltd |
Sirna for inhibiting dgat2 gene expression, sirna conjugate or prodrug and pharmaceutical composition thereof, and use thereof
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025040139A1
(zh)
|
2023-08-23 |
2025-02-27 |
云合智药（苏州）生物科技有限公司 |
用于抑制二酰甘油-O-酰基转移酶2表达的RNAi剂及其应用
|
|
CN121729496A
(zh)
|
2023-08-31 |
2026-03-24 |
正大天晴药业集团股份有限公司 |
靶向凝血因子xi的双链核糖核酸
|
|
WO2025064660A2
(en)
|
2023-09-21 |
2025-03-27 |
Alnylam Pharmaceuticals, Inc. |
Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
|
|
GB202314724D0
(en)
|
2023-09-26 |
2023-11-08 |
Astrazeneca Ab |
compounds and methods for reducing psd3 expression
|
|
WO2025072672A2
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Slc6a19-targeting modulatory nucleic acid agents
|
|
WO2025072699A1
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Aminoglycosides for delivery of agents to the kidney
|
|
WO2025072713A1
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Polymyxins for delivery of agents to the kidney
|
|
WO2025076031A2
(en)
|
2023-10-03 |
2025-04-10 |
Alnylam Pharmaceuticals, Inc. |
Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
|
|
AU2024360411A1
(en)
|
2023-10-10 |
2026-02-26 |
Avanti Polar Lipids, Llc |
Liver asialoglycoprotein receptor targeted lipid and uses thereof
|
|
EP4695265A1
(en)
|
2023-10-16 |
2026-02-18 |
Bachem Holding AG |
Method and composition for oligonucleotide synthesis
|
|
WO2025085732A1
(en)
|
2023-10-18 |
2025-04-24 |
Sarepta Therapeutics, Inc. |
Humanized dnm2 mouse model generation, characterization and methods of use
|
|
WO2025090796A1
(en)
*
|
2023-10-24 |
2025-05-01 |
University Of Connecticut |
Carbohydrate ligands and uses thereof
|
|
CN121909203A
(zh)
|
2023-10-31 |
2026-04-21 |
科罗生物公司 |
包含氨基磷酸酯核苷酸间键的寡核苷酸
|
|
WO2025097126A1
(en)
*
|
2023-11-03 |
2025-05-08 |
Vionelix Pharmaceuticals, Inc. |
Mutation-resistant anti-viral compositions
|
|
WO2025077949A1
(zh)
*
|
2023-11-06 |
2025-04-17 |
杭州天龙药业有限公司 |
提升双链寡核苷酸靶基因抑制效果的修饰模板及其组合与应用
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
TW202546227A
(zh)
|
2024-01-18 |
2025-12-01 |
荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ |
用於治療賀勒氏症候群（ｈｕｒｌｅｒ ｓｙｎｄｒｏｍｅ）的反義寡核苷酸
|
|
WO2025157273A1
(en)
*
|
2024-01-25 |
2025-07-31 |
Shanghai Rona Therapeutics Co., Ltd. |
Two or more nucleic acid molecules connected by a linker
|
|
WO2025165891A1
(en)
|
2024-01-29 |
2025-08-07 |
Arnatar Therapeutics, Inc |
Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
|
|
EP4671372A3
(en)
|
2024-01-29 |
2026-03-11 |
Arnatar Therapeutics, Inc |
Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
|
|
WO2025193807A1
(en)
|
2024-03-12 |
2025-09-18 |
Sarepta Therapeutics, Inc. |
Humanized umod mouse model generation, characterization and methods of use
|
|
GB202404661D0
(en)
|
2024-04-02 |
2024-05-15 |
Proqr Therapeutics Ii Bv |
Antisense oligoncleotides for the treatment of liver disease
|
|
WO2025224036A1
(en)
|
2024-04-22 |
2025-10-30 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
WO2025224230A1
(en)
|
2024-04-25 |
2025-10-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of fatty liver disease
|
|
WO2025228441A2
(en)
|
2024-04-30 |
2025-11-06 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting inhbe and uses thereof
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025260068A1
(en)
|
2024-06-14 |
2025-12-18 |
Tune Therapeutics, Inc. |
Lipid nanoparticle formulation for delivery of nucleic acids to cells
|
|
WO2025260042A1
(en)
|
2024-06-14 |
2025-12-18 |
Amgen Inc. |
Rnai constructs and methods for inhibiting cnr1 expression
|
|
WO2026006436A1
(en)
|
2024-06-25 |
2026-01-02 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
|
|
WO2026006275A2
(en)
|
2024-06-26 |
2026-01-02 |
Amgen Inc. |
Rnai constructs and methods for inhibiting expression of inhbe
|
|
GB202410081D0
(en)
|
2024-07-11 |
2024-08-28 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
US20260015617A1
(en)
|
2024-07-12 |
2026-01-15 |
Novartis Ag |
DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE
|
|
WO2026017140A2
(en)
|
2024-07-18 |
2026-01-22 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting fxi and uses thereof
|
|
WO2026027887A2
(en)
|
2024-08-02 |
2026-02-05 |
Mina Therapeutics Limited |
Hbg1/2-sarna compositions and methods of use
|
|
WO2026041067A2
(en)
|
2024-08-20 |
2026-02-26 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting myostatin (mstn) and uses thereof
|
|
WO2026044153A1
(en)
|
2024-08-21 |
2026-02-26 |
Bpgbio, Inc. |
Use of biomarkers in the diagnosis of pancreatic cancer
|
|
WO2026050243A1
(en)
|
2024-08-26 |
2026-03-05 |
Korro Bio, Inc. |
Galnac conjugated oligonucleotides for rna editing
|
|
WO2026046411A1
(en)
|
2024-09-02 |
2026-03-05 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting plasminogen (plg) and uses thereof
|